Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 7/20 | 0.39 |
| ▸ | HRH1 | P35367 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL718575 | 0.99 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBLMNATSHRDPP4 | |
| Hydrochloric Acid SCHEMBL718574 | 0.99 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBLMNATSHRDPP4 | |
| SCHEMBL694227 | 0.87 | P2RY12 (0.46) | SMN1; SMN2POLBLMNAP2RY12 | |
| SCHEMBL693694 | 0.87 | P2RY12 (0.46) | SMN1; SMN2POLBLMNAP2RY12 | |
| SCHEMBL522823 | 0.87 | LMNA (0.54) | SMN1; SMN2POLBLMNATSHRDPP4 | |
| SCHEMBL522822 | 0.87 | LMNA (0.54) | SMN1; SMN2POLBLMNATSHRDPP4 | |
| SCHEMBL523224 | 0.87 | LMNA (0.54) | SMN1; SMN2POLBLMNATSHRDPP4 | |
| SCHEMBL523223 | 0.87 | LMNA (0.54) | SMN1; SMN2POLBLMNATSHRDPP4 | |
| Acetic Acid SCHEMBL317606 | 0.84 | P2RY12 (0.47) | SMN1; SMN2POLBLMNAP2RY12 | |
| SCHEMBL3331715 | 0.83 | LMNA (0.50) | SMN1; SMN2POLBLMNAP2RY12HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664203-B2 | Thiazole derivatives and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-01 | — | — | US | disclosed |
| EP-2421859-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122504-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | SMN1; SMN2 3623/4885POLB 4348/4885LMNA 3423/4885 |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | SMN1; SMN2 3642/4885POLB 4457/4885LMNA 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.